Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy. 1993

Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

We studied the production of cytokines by peripheral blood monocytes and T cells during the period of haematological recovery following intensive chemotherapy. Twelve adults with haematological malignancies received consolidation chemotherapy of complete remission. Monocytes and T cells were collected during the phase of recovery from intensive chemotherapy, and were incubated for 24 h in a culture medium with 10% FCS. Concentrations of cytokines in the culture supernatant were measured with an enzyme-linked immunosorbent assay. During the recovery phase, concentrations of IL-6, G-CSF and IL-1 beta in the culture supernatant of the collected monocytes significantly exceeded those of the monocytes obtained from normal healthy subjects. Similarly, the concentrations of GM-CSF and IFN-gamma in the supernatant of recovery phase T cells significantly exceeded those of normal T cells. Plasma levels of these cytokines were also elevated. These data suggest that the monocytes and T cells may be activated in vivo to produce haemopoietic cytokines during haematological recovery, and that, during haematological recovery, the monocytes and T cells may be actively involved in the induction of haematopoiesis following the myelosuppression induced by chemotherapy.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
June 2003, Human reproduction (Oxford, England),
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
March 2000, Acta neurologica Scandinavica,
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
April 1993, Acta neurologica Scandinavica,
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
January 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
January 2010, Clinical & developmental immunology,
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
March 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
January 1999, Pharmacological research,
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
August 1991, Bone and mineral,
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
September 1996, Bone marrow transplantation,
Y Takamatsu, and K Akashi, and M Harada, and T Teshima, and S Inaba, and K Shimoda, and T Eto, and T Shibuya, and S Okamura, and Y Niho
November 2004, Renal failure,
Copied contents to your clipboard!